Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - BELLICUM PHARMACEUTICALS, INC | bellicum-programupdates.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________________________________________________________
FORM 8-K
_____________________________________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
January 11, 2016
Date of Report (Date of earliest event reported)
_____________________________________________________________________________________________
Bellicum Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
_____________________________________________________________________________________________
Delaware | 001-36783 | 20-1450200 | ||
(State or other jurisdiction | (Commission File Number) | (IRS Employer Identification No.) | ||
of incorporation) | ||||
2130 W. Holcombe Blvd., Ste. 800 Houston, TX | 77030 | |||
(Address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: 832-384-1100
_____________________________________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
_____________________________________________________________________________________________
Item 8.01 | Other Events. |
On January 11, 2016, Bellicum Pharmaceuticals, Inc. (the “Company”) issued a press release announcing program updates on its CAR T and TCR product candidates, including updates regarding the expected timing for the enrollment of patients in clinical trials for the Company’s most advanced CAR T and TCR adoptive cell therapy programs, BPX-701, BPX-601 and BPX-401. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information contained in this Current Report on Form 8-K and in the accompanying Exhibit 99.1 are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is being disclosed pursuant to Regulation FD.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number | Description | |
99.1 | Press Release dated January 11, 2016 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Bellicum Pharmaceuticals, Inc. | ||||||
Dated: January 11, 2016 | By: | /s/ Ken Moseley | ||||
Ken Moseley | ||||||
Senior Vice President and General Counsel | ||||||
INDEX TO EXHIBITS
Exhibit No. | Description | |
99.1 | Press Release dated January 11, 2016 | |